| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 32 | 2023 | 329 | 6.940 |
Why?
|
| Biopsy, Fine-Needle | 31 | 2022 | 50 | 4.380 |
Why?
|
| Lung Neoplasms | 25 | 2020 | 625 | 3.390 |
Why?
|
| Biomarkers, Tumor | 23 | 2020 | 175 | 3.340 |
Why?
|
| Middle Aged | 138 | 2023 | 9823 | 3.220 |
Why?
|
| Liver Neoplasms | 14 | 2018 | 103 | 3.040 |
Why?
|
| Biopsy, Needle | 44 | 2020 | 101 | 2.920 |
Why?
|
| Skin Neoplasms | 12 | 2022 | 65 | 2.900 |
Why?
|
| Carcinoma | 12 | 2017 | 57 | 2.890 |
Why?
|
| Female | 157 | 2023 | 16211 | 2.880 |
Why?
|
| Carcinoma, Lobular | 6 | 2022 | 13 | 2.870 |
Why?
|
| Humans | 220 | 2023 | 29361 | 2.790 |
Why?
|
| Thyroid Neoplasms | 15 | 2020 | 37 | 2.730 |
Why?
|
| Ovarian Neoplasms | 7 | 2022 | 46 | 2.510 |
Why?
|
| Adult | 102 | 2023 | 8604 | 2.410 |
Why?
|
| Sinusitis | 17 | 2023 | 187 | 2.380 |
Why?
|
| Rhinitis | 17 | 2023 | 165 | 2.260 |
Why?
|
| Carcinoma, Ductal, Breast | 7 | 2022 | 24 | 2.240 |
Why?
|
| Retrospective Studies | 52 | 2023 | 3273 | 2.150 |
Why?
|
| Male | 132 | 2021 | 15637 | 2.100 |
Why?
|
| Diagnosis, Differential | 32 | 2023 | 389 | 2.100 |
Why?
|
| Aged | 97 | 2023 | 9447 | 2.050 |
Why?
|
| Adenocarcinoma | 16 | 2020 | 189 | 2.000 |
Why?
|
| Lymphoma | 11 | 2017 | 44 | 1.890 |
Why?
|
| Immunohistochemistry | 38 | 2019 | 391 | 1.870 |
Why?
|
| Adenoma | 10 | 2023 | 42 | 1.820 |
Why?
|
| Neoplasms, Multiple Primary | 11 | 2020 | 31 | 1.790 |
Why?
|
| Bone Neoplasms | 9 | 2022 | 102 | 1.700 |
Why?
|
| Lymphatic Metastasis | 11 | 2019 | 81 | 1.690 |
Why?
|
| Urinary Bladder Neoplasms | 5 | 2019 | 26 | 1.660 |
Why?
|
| Head and Neck Neoplasms | 4 | 2021 | 133 | 1.600 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2023 | 184 | 1.560 |
Why?
|
| Stromal Cells | 5 | 2020 | 35 | 1.560 |
Why?
|
| Carcinoma, Hepatocellular | 6 | 2018 | 32 | 1.550 |
Why?
|
| Kidney Neoplasms | 9 | 2017 | 60 | 1.540 |
Why?
|
| Thyroid Gland | 5 | 2020 | 27 | 1.490 |
Why?
|
| Carcinoma, Neuroendocrine | 6 | 2022 | 7 | 1.430 |
Why?
|
| Pancreatic Neoplasms | 12 | 2014 | 142 | 1.430 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 5 | 2020 | 22 | 1.430 |
Why?
|
| Aged, 80 and over | 47 | 2020 | 4851 | 1.360 |
Why?
|
| Pleural Effusion | 3 | 2019 | 10 | 1.340 |
Why?
|
| Lymph Nodes | 9 | 2022 | 70 | 1.320 |
Why?
|
| Soft Tissue Neoplasms | 4 | 2018 | 24 | 1.280 |
Why?
|
| Carcinoma, Squamous Cell | 10 | 2021 | 178 | 1.270 |
Why?
|
| Breast Neoplasms, Male | 6 | 2017 | 9 | 1.230 |
Why?
|
| Nasal Polyps | 9 | 2023 | 62 | 1.230 |
Why?
|
| Granulosa Cell Tumor | 3 | 2016 | 3 | 1.230 |
Why?
|
| Carcinoma, Signet Ring Cell | 2 | 2018 | 3 | 1.220 |
Why?
|
| Melanoma | 8 | 2020 | 52 | 1.130 |
Why?
|
| Hemangioma | 3 | 2023 | 8 | 1.120 |
Why?
|
| Sarcoma | 7 | 2021 | 65 | 1.120 |
Why?
|
| Neoplasm Proteins | 6 | 2015 | 50 | 1.100 |
Why?
|
| Ependymoma | 4 | 2013 | 11 | 1.090 |
Why?
|
| Ear Neoplasms | 2 | 2023 | 6 | 1.080 |
Why?
|
| Neoplasms | 7 | 2020 | 247 | 1.050 |
Why?
|
| Ascitic Fluid | 3 | 2016 | 10 | 0.960 |
Why?
|
| Adenocarcinoma, Papillary | 2 | 2022 | 3 | 0.960 |
Why?
|
| Carcinoma, Basal Cell | 2 | 2020 | 7 | 0.950 |
Why?
|
| Biopsy | 10 | 2021 | 234 | 0.930 |
Why?
|
| Cytodiagnosis | 11 | 2020 | 15 | 0.930 |
Why?
|
| Blastomycosis | 3 | 2019 | 16 | 0.920 |
Why?
|
| Thymus Neoplasms | 2 | 2020 | 12 | 0.920 |
Why?
|
| Fibroadenoma | 2 | 2022 | 3 | 0.910 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2022 | 8 | 0.900 |
Why?
|
| Bronchial Neoplasms | 2 | 2017 | 5 | 0.890 |
Why?
|
| Paranasal Sinuses | 7 | 2020 | 63 | 0.880 |
Why?
|
| Receptor, ErbB-2 | 8 | 2020 | 41 | 0.880 |
Why?
|
| Adolescent | 28 | 2021 | 2280 | 0.880 |
Why?
|
| Carcinoma, Transitional Cell | 2 | 2014 | 12 | 0.870 |
Why?
|
| Neoplasms, Second Primary | 3 | 2020 | 30 | 0.860 |
Why?
|
| Endolymphatic Sac | 1 | 2022 | 2 | 0.860 |
Why?
|
| Carcinoma, Papillary | 10 | 2012 | 20 | 0.860 |
Why?
|
| Parathyroid Neoplasms | 2 | 2020 | 5 | 0.850 |
Why?
|
| Endometriosis | 3 | 2018 | 13 | 0.840 |
Why?
|
| Lymphocytes | 4 | 2020 | 110 | 0.820 |
Why?
|
| Hematologic Neoplasms | 2 | 2017 | 17 | 0.810 |
Why?
|
| Salivary Gland Neoplasms | 3 | 2020 | 7 | 0.810 |
Why?
|
| Sensitivity and Specificity | 15 | 2021 | 553 | 0.800 |
Why?
|
| Parotid Neoplasms | 5 | 2022 | 13 | 0.790 |
Why?
|
| Granular Cell Tumor | 2 | 2018 | 5 | 0.780 |
Why?
|
| Organ Transplantation | 5 | 2005 | 35 | 0.780 |
Why?
|
| Carcinoma, Renal Cell | 4 | 2017 | 35 | 0.770 |
Why?
|
| Thyroid Carcinoma, Anaplastic | 1 | 2020 | 1 | 0.770 |
Why?
|
| Liposarcoma | 1 | 2020 | 5 | 0.770 |
Why?
|
| Carcinoma, Acinar Cell | 1 | 2020 | 4 | 0.770 |
Why?
|
| Parathyroid Glands | 1 | 2020 | 7 | 0.760 |
Why?
|
| Vulvar Neoplasms | 1 | 2020 | 3 | 0.760 |
Why?
|
| Neoplasm Metastasis | 6 | 2020 | 101 | 0.760 |
Why?
|
| Neoplasm Invasiveness | 9 | 2021 | 68 | 0.760 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2020 | 29 | 0.750 |
Why?
|
| Mammary Analogue Secretory Carcinoma | 1 | 2020 | 1 | 0.750 |
Why?
|
| Papillomavirus Infections | 1 | 2020 | 37 | 0.750 |
Why?
|
| Adrenocortical Carcinoma | 3 | 2020 | 6 | 0.740 |
Why?
|
| Neuroendocrine Tumors | 4 | 2022 | 17 | 0.740 |
Why?
|
| Adenocarcinoma, Follicular | 4 | 2018 | 5 | 0.740 |
Why?
|
| Young Adult | 15 | 2021 | 1935 | 0.740 |
Why?
|
| Cell Nucleus | 6 | 2016 | 79 | 0.730 |
Why?
|
| Postoperative Complications | 6 | 2018 | 957 | 0.730 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2019 | 14 | 0.730 |
Why?
|
| Paraganglioma | 1 | 2019 | 2 | 0.720 |
Why?
|
| Rhabdomyosarcoma | 3 | 2010 | 4 | 0.700 |
Why?
|
| Receptors, Estrogen | 8 | 2022 | 58 | 0.690 |
Why?
|
| Fibroblasts | 1 | 2019 | 95 | 0.690 |
Why?
|
| Cytoplasm | 4 | 2014 | 36 | 0.680 |
Why?
|
| Histiocytes | 2 | 2018 | 4 | 0.680 |
Why?
|
| Transplant Recipients | 1 | 2018 | 23 | 0.680 |
Why?
|
| In Situ Hybridization, Fluorescence | 8 | 2020 | 29 | 0.670 |
Why?
|
| Multiple Myeloma | 4 | 2016 | 30 | 0.670 |
Why?
|
| Chronic Disease | 17 | 2023 | 495 | 0.660 |
Why?
|
| Angiomyolipoma | 2 | 2015 | 2 | 0.660 |
Why?
|
| Umbilicus | 1 | 2018 | 1 | 0.650 |
Why?
|
| Brain Neoplasms | 3 | 2016 | 124 | 0.650 |
Why?
|
| Epidermal Cyst | 1 | 2018 | 6 | 0.650 |
Why?
|
| Pleural Effusion, Malignant | 1 | 2018 | 3 | 0.640 |
Why?
|
| Cytological Techniques | 4 | 2021 | 14 | 0.630 |
Why?
|
| Sarcoma, Myeloid | 1 | 2017 | 4 | 0.630 |
Why?
|
| Liver Transplantation | 1 | 2018 | 79 | 0.620 |
Why?
|
| Plasmacytoma | 1 | 2017 | 18 | 0.620 |
Why?
|
| Prognosis | 18 | 2019 | 840 | 0.610 |
Why?
|
| Meningeal Carcinomatosis | 1 | 2017 | 1 | 0.610 |
Why?
|
| Pericardial Effusion | 2 | 2016 | 4 | 0.600 |
Why?
|
| Bronchoalveolar Lavage Fluid | 2 | 2012 | 16 | 0.600 |
Why?
|
| Uterine Neoplasms | 2 | 2016 | 8 | 0.590 |
Why?
|
| Cerebrospinal Fluid | 1 | 2016 | 18 | 0.580 |
Why?
|
| Pelvic Neoplasms | 1 | 2016 | 7 | 0.580 |
Why?
|
| Vaginal Neoplasms | 1 | 2016 | 1 | 0.570 |
Why?
|
| Thyroid Nodule | 2 | 2015 | 7 | 0.570 |
Why?
|
| Eosinophils | 4 | 2022 | 47 | 0.570 |
Why?
|
| Ovarian Cysts | 1 | 2016 | 5 | 0.570 |
Why?
|
| Sarcoma, Synovial | 1 | 2015 | 3 | 0.540 |
Why?
|
| Rare Diseases | 2 | 2015 | 11 | 0.540 |
Why?
|
| Myoepithelioma | 1 | 2015 | 2 | 0.540 |
Why?
|
| Granulomatous Mastitis | 1 | 2015 | 1 | 0.530 |
Why?
|
| Lymphoproliferative Disorders | 5 | 2005 | 19 | 0.520 |
Why?
|
| Pulmonary Blastoma | 2 | 2015 | 3 | 0.520 |
Why?
|
| Databases, Factual | 5 | 2023 | 330 | 0.510 |
Why?
|
| Pineal Gland | 1 | 2014 | 3 | 0.490 |
Why?
|
| Cystitis | 2 | 2019 | 11 | 0.490 |
Why?
|
| Urine | 2 | 2019 | 9 | 0.490 |
Why?
|
| Pathology | 1 | 2014 | 4 | 0.490 |
Why?
|
| Angiolipoma | 1 | 2014 | 1 | 0.490 |
Why?
|
| Receptors, Androgen | 1 | 2014 | 6 | 0.490 |
Why?
|
| Meningeal Neoplasms | 3 | 2008 | 13 | 0.490 |
Why?
|
| Hemangiosarcoma | 1 | 2014 | 3 | 0.480 |
Why?
|
| Adipocytes | 1 | 2014 | 11 | 0.480 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 2013 | 2 | 0.480 |
Why?
|
| Intraoperative Care | 1 | 2014 | 44 | 0.480 |
Why?
|
| Eosinophilia | 5 | 2019 | 47 | 0.470 |
Why?
|
| Leukemia | 2 | 2012 | 10 | 0.470 |
Why?
|
| Wilms Tumor | 1 | 2013 | 8 | 0.460 |
Why?
|
| Urinary Bladder | 2 | 2016 | 20 | 0.450 |
Why?
|
| Vitreous Body | 1 | 2012 | 7 | 0.430 |
Why?
|
| Receptors, Progesterone | 6 | 2017 | 27 | 0.430 |
Why?
|
| Eye Diseases | 1 | 2012 | 7 | 0.430 |
Why?
|
| Tumor Virus Infections | 2 | 2009 | 15 | 0.420 |
Why?
|
| Breast | 4 | 2023 | 16 | 0.420 |
Why?
|
| Histiocytosis, Sinus | 1 | 2011 | 3 | 0.420 |
Why?
|
| Pulmonary Sclerosing Hemangioma | 1 | 2011 | 1 | 0.410 |
Why?
|
| Alveolar Epithelial Cells | 1 | 2011 | 1 | 0.410 |
Why?
|
| Bone Diseases | 1 | 2011 | 24 | 0.410 |
Why?
|
| Glucuronidase | 6 | 2007 | 10 | 0.400 |
Why?
|
| Neoplasm Staging | 10 | 2018 | 340 | 0.400 |
Why?
|
| Urologic Neoplasms | 1 | 2011 | 3 | 0.390 |
Why?
|
| Carcinoid Tumor | 3 | 2008 | 8 | 0.390 |
Why?
|
| Hodgkin Disease | 3 | 2006 | 19 | 0.380 |
Why?
|
| Lymphoma, T-Cell | 2 | 2017 | 5 | 0.380 |
Why?
|
| Papilloma | 1 | 2009 | 3 | 0.370 |
Why?
|
| Carcinoma, Medullary | 3 | 2022 | 5 | 0.370 |
Why?
|
| Alphapapillomavirus | 1 | 2009 | 6 | 0.370 |
Why?
|
| Thyroid Diseases | 1 | 2009 | 14 | 0.360 |
Why?
|
| Adrenal Cortex Neoplasms | 2 | 2020 | 5 | 0.360 |
Why?
|
| DNA, Neoplasm | 4 | 2010 | 25 | 0.360 |
Why?
|
| Salivary Glands | 3 | 2020 | 4 | 0.360 |
Why?
|
| Polyomavirus Infections | 1 | 2009 | 22 | 0.350 |
Why?
|
| Paranasal Sinus Neoplasms | 3 | 2018 | 53 | 0.350 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2009 | 13 | 0.350 |
Why?
|
| Breast Diseases | 4 | 2005 | 6 | 0.350 |
Why?
|
| Age Factors | 4 | 2019 | 845 | 0.350 |
Why?
|
| Flow Cytometry | 8 | 2012 | 199 | 0.340 |
Why?
|
| Gene Amplification | 3 | 2005 | 19 | 0.340 |
Why?
|
| Chondroma | 1 | 2008 | 3 | 0.340 |
Why?
|
| Genital Neoplasms, Female | 2 | 2022 | 10 | 0.340 |
Why?
|
| Prevalence | 2 | 2020 | 491 | 0.330 |
Why?
|
| Neoplasm Grading | 3 | 2017 | 45 | 0.330 |
Why?
|
| Nasal Mucosa | 2 | 2018 | 16 | 0.330 |
Why?
|
| Kidney Diseases | 1 | 2009 | 115 | 0.320 |
Why?
|
| Skin | 3 | 2020 | 117 | 0.320 |
Why?
|
| Meningioma | 1 | 2008 | 18 | 0.320 |
Why?
|
| Smoking | 4 | 2020 | 194 | 0.320 |
Why?
|
| Illinois | 5 | 2019 | 241 | 0.320 |
Why?
|
| Survival Analysis | 8 | 2017 | 298 | 0.320 |
Why?
|
| Pancreas | 4 | 2000 | 32 | 0.320 |
Why?
|
| Fibrocystic Breast Disease | 3 | 2005 | 4 | 0.320 |
Why?
|
| Kidney Transplantation | 4 | 2019 | 125 | 0.320 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2011 | 16 | 0.310 |
Why?
|
| Neutrophils | 2 | 2018 | 117 | 0.310 |
Why?
|
| Endoscopy | 8 | 2023 | 181 | 0.310 |
Why?
|
| Incidence | 6 | 2019 | 756 | 0.310 |
Why?
|
| Precancerous Conditions | 4 | 2013 | 22 | 0.310 |
Why?
|
| Adenoma, Pleomorphic | 2 | 2004 | 6 | 0.310 |
Why?
|
| Liver | 4 | 2002 | 173 | 0.310 |
Why?
|
| Reed-Sternberg Cells | 1 | 2006 | 1 | 0.300 |
Why?
|
| Bronchi | 1 | 2006 | 12 | 0.300 |
Why?
|
| Chondrocytes | 1 | 2008 | 197 | 0.300 |
Why?
|
| Carcinoma, Large Cell | 1 | 2006 | 15 | 0.300 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 3 | 2017 | 18 | 0.290 |
Why?
|
| Ploidies | 4 | 1999 | 6 | 0.280 |
Why?
|
| Genes, erbB-2 | 2 | 2005 | 6 | 0.280 |
Why?
|
| Panniculitis | 2 | 2010 | 4 | 0.280 |
Why?
|
| Pleural Neoplasms | 1 | 2006 | 9 | 0.280 |
Why?
|
| Mesothelioma | 1 | 2006 | 10 | 0.280 |
Why?
|
| Adenocarcinoma, Clear Cell | 2 | 2015 | 3 | 0.280 |
Why?
|
| Stomach Neoplasms | 2 | 2017 | 30 | 0.270 |
Why?
|
| Thymoma | 2 | 2017 | 13 | 0.270 |
Why?
|
| Parotid Gland | 3 | 2022 | 15 | 0.270 |
Why?
|
| Immunocompromised Host | 3 | 2019 | 45 | 0.270 |
Why?
|
| Proto-Oncogene Proteins B-raf | 4 | 2018 | 5 | 0.270 |
Why?
|
| Predictive Value of Tests | 11 | 2015 | 521 | 0.270 |
Why?
|
| Osteomyelitis | 3 | 2014 | 22 | 0.260 |
Why?
|
| Cell Differentiation | 2 | 2017 | 146 | 0.260 |
Why?
|
| Streptococcus agalactiae | 2 | 2019 | 8 | 0.260 |
Why?
|
| Hematuria | 2 | 2019 | 15 | 0.260 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2004 | 9 | 0.260 |
Why?
|
| Antigens, CD | 3 | 2017 | 99 | 0.260 |
Why?
|
| Cytomegalovirus Infections | 2 | 1997 | 79 | 0.250 |
Why?
|
| Inflammation | 4 | 2023 | 345 | 0.240 |
Why?
|
| Leiomyosarcoma | 2 | 2017 | 7 | 0.240 |
Why?
|
| Abdominal Neoplasms | 2 | 2002 | 9 | 0.240 |
Why?
|
| Papilloma, Inverted | 1 | 2004 | 14 | 0.240 |
Why?
|
| Lymphatic Diseases | 1 | 2003 | 2 | 0.240 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2021 | 51 | 0.240 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 2 | 2021 | 28 | 0.240 |
Why?
|
| Paget's Disease, Mammary | 1 | 2003 | 1 | 0.230 |
Why?
|
| Thyroiditis, Autoimmune | 2 | 1996 | 3 | 0.230 |
Why?
|
| Angiomatosis | 1 | 2023 | 2 | 0.230 |
Why?
|
| Lupus Erythematosus, Systemic | 2 | 2020 | 202 | 0.230 |
Why?
|
| Scalp | 2 | 2000 | 6 | 0.220 |
Why?
|
| Krukenberg Tumor | 1 | 2022 | 1 | 0.220 |
Why?
|
| Proliferating Cell Nuclear Antigen | 2 | 2002 | 9 | 0.220 |
Why?
|
| Blastomyces | 2 | 2014 | 8 | 0.220 |
Why?
|
| Programmed Cell Death 1 Ligand 2 Protein | 2 | 2020 | 2 | 0.220 |
Why?
|
| Fibroma | 2 | 2015 | 2 | 0.220 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2022 | 4 | 0.220 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2020 | 18 | 0.220 |
Why?
|
| Adrenal Gland Neoplasms | 5 | 2011 | 11 | 0.220 |
Why?
|
| Bile Duct Neoplasms | 1 | 2002 | 12 | 0.210 |
Why?
|
| Calcinosis | 2 | 2005 | 47 | 0.210 |
Why?
|
| Nuclear Proteins | 2 | 2002 | 89 | 0.210 |
Why?
|
| Adenocarcinoma in Situ | 1 | 2021 | 1 | 0.210 |
Why?
|
| Papanicolaou Test | 1 | 2021 | 10 | 0.210 |
Why?
|
| Hedgehog Proteins | 2 | 2012 | 10 | 0.200 |
Why?
|
| Hysterectomy | 1 | 2021 | 19 | 0.200 |
Why?
|
| Diabetes Mellitus | 1 | 2023 | 137 | 0.200 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2017 | 24 | 0.200 |
Why?
|
| Rectal Neoplasms | 2 | 2020 | 19 | 0.200 |
Why?
|
| Survival Rate | 4 | 2018 | 349 | 0.200 |
Why?
|
| Gloves, Surgical | 1 | 2021 | 7 | 0.200 |
Why?
|
| Air Pollution | 1 | 2021 | 17 | 0.200 |
Why?
|
| Neoplasm Seeding | 1 | 2021 | 7 | 0.200 |
Why?
|
| Air Pollutants | 1 | 2021 | 12 | 0.200 |
Why?
|
| Surgical Instruments | 1 | 2021 | 25 | 0.190 |
Why?
|
| Tumor Cells, Cultured | 2 | 2019 | 145 | 0.190 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2020 | 2 | 0.190 |
Why?
|
| Paget Disease, Extramammary | 1 | 2020 | 1 | 0.190 |
Why?
|
| Dermatofibrosarcoma | 1 | 2020 | 1 | 0.190 |
Why?
|
| Endometrium | 2 | 2013 | 7 | 0.190 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2020 | 6 | 0.190 |
Why?
|
| B7-H1 Antigen | 1 | 2020 | 13 | 0.190 |
Why?
|
| Heart Neoplasms | 3 | 1996 | 13 | 0.190 |
Why?
|
| Amino Acid Substitution | 2 | 2018 | 26 | 0.190 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2019 | 5 | 0.180 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2019 | 7 | 0.180 |
Why?
|
| Colonic Neoplasms | 3 | 2017 | 66 | 0.180 |
Why?
|
| Fibrosis | 4 | 2018 | 39 | 0.180 |
Why?
|
| Spinal Diseases | 2 | 2007 | 150 | 0.180 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 1999 | 4 | 0.180 |
Why?
|
| Thoracic Neoplasms | 2 | 1996 | 9 | 0.170 |
Why?
|
| Chondrosarcoma | 2 | 2008 | 31 | 0.170 |
Why?
|
| Lung Diseases | 1 | 2019 | 46 | 0.170 |
Why?
|
| Vaginal Smears | 2 | 2016 | 17 | 0.170 |
Why?
|
| Cell Movement | 1 | 2019 | 105 | 0.170 |
Why?
|
| GTP Phosphohydrolases | 1 | 2018 | 3 | 0.170 |
Why?
|
| Maxillary Diseases | 1 | 2018 | 3 | 0.170 |
Why?
|
| Insurance Coverage | 1 | 2019 | 13 | 0.170 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2013 | 89 | 0.170 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 2011 | 19 | 0.170 |
Why?
|
| Galectin 3 | 1 | 2018 | 3 | 0.170 |
Why?
|
| Galectins | 1 | 2018 | 6 | 0.170 |
Why?
|
| Sacrococcygeal Region | 2 | 1996 | 3 | 0.170 |
Why?
|
| Blood Proteins | 1 | 2018 | 20 | 0.170 |
Why?
|
| Mutation, Missense | 1 | 2018 | 22 | 0.170 |
Why?
|
| Bacteroidetes | 1 | 2018 | 4 | 0.170 |
Why?
|
| Firmicutes | 1 | 2018 | 6 | 0.170 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2018 | 17 | 0.170 |
Why?
|
| Abdominal Muscles | 1 | 1998 | 7 | 0.170 |
Why?
|
| Cell Proliferation | 2 | 2018 | 202 | 0.170 |
Why?
|
| Sex Factors | 2 | 2019 | 496 | 0.170 |
Why?
|
| Tongue Neoplasms | 1 | 2018 | 16 | 0.170 |
Why?
|
| Prednisone | 1 | 2018 | 67 | 0.170 |
Why?
|
| Severity of Illness Index | 6 | 2019 | 1113 | 0.160 |
Why?
|
| Peritoneal Neoplasms | 2 | 2011 | 5 | 0.160 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2012 | 316 | 0.160 |
Why?
|
| Epithelial Cells | 3 | 2015 | 88 | 0.160 |
Why?
|
| Time Factors | 4 | 2017 | 1618 | 0.160 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 290 | 0.160 |
Why?
|
| Diagnostic Errors | 1 | 2018 | 40 | 0.160 |
Why?
|
| Lung Transplantation | 2 | 1997 | 18 | 0.160 |
Why?
|
| Pancreatectomy | 2 | 2014 | 10 | 0.160 |
Why?
|
| Synaptophysin | 1 | 2017 | 9 | 0.160 |
Why?
|
| Chromogranin A | 1 | 2017 | 13 | 0.160 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2017 | 1 | 0.160 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2017 | 3 | 0.160 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2018 | 100 | 0.160 |
Why?
|
| Lymphoma, Follicular | 1 | 2017 | 4 | 0.160 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2017 | 6 | 0.160 |
Why?
|
| Burkitt Lymphoma | 1 | 2017 | 7 | 0.160 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2017 | 6 | 0.160 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2017 | 3 | 0.160 |
Why?
|
| Tomography, X-Ray Computed | 8 | 2009 | 770 | 0.160 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2012 | 44 | 0.160 |
Why?
|
| Hypertension | 1 | 2020 | 266 | 0.160 |
Why?
|
| Nose Neoplasms | 1 | 2018 | 34 | 0.150 |
Why?
|
| Carcinoma, Embryonal | 1 | 2017 | 3 | 0.150 |
Why?
|
| Genes, BRCA2 | 1 | 2017 | 8 | 0.150 |
Why?
|
| Tonsillar Neoplasms | 1 | 2017 | 3 | 0.150 |
Why?
|
| Genes, BRCA1 | 1 | 2017 | 9 | 0.150 |
Why?
|
| Immunosuppressive Agents | 1 | 2018 | 132 | 0.150 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2017 | 10 | 0.150 |
Why?
|
| Neovascularization, Pathologic | 2 | 2014 | 56 | 0.150 |
Why?
|
| Pituitary Neoplasms | 1 | 2017 | 20 | 0.150 |
Why?
|
| Ethmoid Sinus | 1 | 2017 | 11 | 0.150 |
Why?
|
| Membrane Proteins | 1 | 2018 | 173 | 0.150 |
Why?
|
| Brain | 2 | 2017 | 1687 | 0.150 |
Why?
|
| Radiation Injuries | 1 | 2017 | 34 | 0.150 |
Why?
|
| Microbiota | 1 | 2018 | 105 | 0.150 |
Why?
|
| Child | 8 | 2022 | 1345 | 0.150 |
Why?
|
| Animals | 8 | 2022 | 4577 | 0.150 |
Why?
|
| Mammography | 2 | 2015 | 34 | 0.150 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2017 | 15 | 0.150 |
Why?
|
| Pancreatitis | 4 | 2000 | 22 | 0.150 |
Why?
|
| Vacuoles | 1 | 2016 | 6 | 0.150 |
Why?
|
| Karyotype | 1 | 2016 | 1 | 0.150 |
Why?
|
| Syndecan-1 | 1 | 2016 | 8 | 0.140 |
Why?
|
| Immunoglobulin A | 1 | 2016 | 19 | 0.140 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2018 | 1220 | 0.140 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2007 | 27 | 0.140 |
Why?
|
| Hyperplasia | 3 | 2005 | 14 | 0.140 |
Why?
|
| Urethral Neoplasms | 1 | 1996 | 1 | 0.140 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2010 | 100 | 0.140 |
Why?
|
| Acute Disease | 5 | 2012 | 226 | 0.140 |
Why?
|
| Histocytological Preparation Techniques | 2 | 2008 | 2 | 0.140 |
Why?
|
| Melanosis | 1 | 1995 | 2 | 0.140 |
Why?
|
| Mediastinal Neoplasms | 1 | 2015 | 12 | 0.140 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 1995 | 10 | 0.140 |
Why?
|
| Testicular Neoplasms | 1 | 2015 | 23 | 0.140 |
Why?
|
| Heparan Sulfate Proteoglycans | 2 | 2006 | 3 | 0.130 |
Why?
|
| Calmodulin-Binding Proteins | 1 | 2015 | 1 | 0.130 |
Why?
|
| Odontogenic Tumors | 1 | 2015 | 1 | 0.130 |
Why?
|
| Mandibular Neoplasms | 1 | 2015 | 2 | 0.130 |
Why?
|
| Polymerase Chain Reaction | 4 | 2009 | 161 | 0.130 |
Why?
|
| RNA-Binding Proteins | 1 | 2015 | 22 | 0.130 |
Why?
|
| Frozen Sections | 2 | 2014 | 11 | 0.130 |
Why?
|
| Ultrasonography, Mammary | 1 | 2015 | 8 | 0.130 |
Why?
|
| Esophageal Neoplasms | 1 | 2015 | 45 | 0.130 |
Why?
|
| Lipoma | 1 | 2015 | 7 | 0.130 |
Why?
|
| Carcinoma in Situ | 2 | 2005 | 9 | 0.130 |
Why?
|
| Tuberous Sclerosis | 1 | 2015 | 14 | 0.130 |
Why?
|
| Treatment Outcome | 7 | 2018 | 3476 | 0.130 |
Why?
|
| Leiomyoma | 1 | 2015 | 10 | 0.130 |
Why?
|
| Reoperation | 1 | 2019 | 933 | 0.130 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 1995 | 4 | 0.130 |
Why?
|
| Parotid Diseases | 1 | 1994 | 1 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 1997 | 89 | 0.130 |
Why?
|
| Tyrosine | 1 | 1994 | 23 | 0.130 |
Why?
|
| Kidney Failure, Chronic | 1 | 1997 | 161 | 0.130 |
Why?
|
| Cysts | 1 | 1994 | 16 | 0.130 |
Why?
|
| Linitis Plastica | 1 | 1994 | 1 | 0.130 |
Why?
|
| Cell Nucleus Shape | 1 | 2014 | 2 | 0.120 |
Why?
|
| Cell Shape | 1 | 2014 | 8 | 0.120 |
Why?
|
| Reproducibility of Results | 5 | 2021 | 788 | 0.120 |
Why?
|
| Mutation | 3 | 2006 | 383 | 0.120 |
Why?
|
| Ki-67 Antigen | 4 | 2014 | 13 | 0.120 |
Why?
|
| Extracellular Space | 1 | 2014 | 13 | 0.120 |
Why?
|
| DNA | 2 | 1994 | 125 | 0.120 |
Why?
|
| Prostatitis | 1 | 1994 | 4 | 0.120 |
Why?
|
| Polysaccharide-Lyases | 2 | 2005 | 5 | 0.120 |
Why?
|
| 12E7 Antigen | 1 | 2013 | 1 | 0.120 |
Why?
|
| Chondromatosis, Synovial | 1 | 1994 | 4 | 0.120 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2013 | 12 | 0.120 |
Why?
|
| Temporomandibular Joint Disorders | 1 | 1994 | 6 | 0.120 |
Why?
|
| Xanthine Dehydrogenase | 2 | 2011 | 6 | 0.120 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2013 | 31 | 0.120 |
Why?
|
| Immunophenotyping | 1 | 2013 | 81 | 0.120 |
Why?
|
| Pneumonectomy | 2 | 2012 | 67 | 0.120 |
Why?
|
| Cell Adhesion Molecules | 1 | 2013 | 40 | 0.120 |
Why?
|
| Prostatic Neoplasms | 1 | 1995 | 106 | 0.120 |
Why?
|
| Cervix Mucus | 1 | 2013 | 4 | 0.120 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2013 | 2 | 0.120 |
Why?
|
| Cerebral Ventricle Neoplasms | 1 | 2013 | 5 | 0.120 |
Why?
|
| Glioma, Subependymal | 1 | 2013 | 5 | 0.120 |
Why?
|
| DNA Mutational Analysis | 1 | 2013 | 56 | 0.120 |
Why?
|
| Postoperative Period | 4 | 2018 | 288 | 0.110 |
Why?
|
| Thyroidectomy | 2 | 2009 | 11 | 0.110 |
Why?
|
| Infant | 2 | 2014 | 531 | 0.110 |
Why?
|
| Genetic Testing | 1 | 2013 | 64 | 0.110 |
Why?
|
| S100 Proteins | 2 | 2011 | 5 | 0.110 |
Why?
|
| Genes, p16 | 1 | 2012 | 4 | 0.110 |
Why?
|
| Infant, Newborn | 2 | 2014 | 604 | 0.110 |
Why?
|
| Dendritic Cells, Follicular | 1 | 2012 | 1 | 0.110 |
Why?
|
| Risk Factors | 1 | 2019 | 2446 | 0.110 |
Why?
|
| Eosinophilic Granuloma | 1 | 2011 | 1 | 0.100 |
Why?
|
| Lymphadenitis | 1 | 2011 | 2 | 0.100 |
Why?
|
| Mesenchymoma | 1 | 2011 | 2 | 0.100 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2011 | 16 | 0.100 |
Why?
|
| Giant Cell Tumor of Bone | 1 | 2011 | 11 | 0.100 |
Why?
|
| DNA Methylation | 1 | 2012 | 124 | 0.100 |
Why?
|
| Disease-Free Survival | 4 | 2018 | 175 | 0.100 |
Why?
|
| HIV Infections | 1 | 1999 | 980 | 0.100 |
Why?
|
| Follow-Up Studies | 6 | 2005 | 1829 | 0.100 |
Why?
|
| Uric Acid | 1 | 2011 | 13 | 0.100 |
Why?
|
| Deoxycytidine | 1 | 2011 | 31 | 0.100 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2011 | 26 | 0.100 |
Why?
|
| Goiter, Nodular | 2 | 2009 | 2 | 0.100 |
Why?
|
| Bacterial Translocation | 3 | 2000 | 33 | 0.100 |
Why?
|
| Terpenes | 1 | 1991 | 4 | 0.100 |
Why?
|
| Specimen Handling | 1 | 2011 | 48 | 0.100 |
Why?
|
| Plant Extracts | 1 | 1991 | 16 | 0.100 |
Why?
|
| Astrocytoma | 1 | 2011 | 24 | 0.100 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2010 | 3 | 0.100 |
Why?
|
| Radiography | 1 | 2013 | 678 | 0.100 |
Why?
|
| Thoracoscopy | 1 | 2010 | 16 | 0.100 |
Why?
|
| Gene Expression | 3 | 2011 | 226 | 0.100 |
Why?
|
| Appendiceal Neoplasms | 1 | 1990 | 3 | 0.100 |
Why?
|
| Staining and Labeling | 1 | 2010 | 22 | 0.100 |
Why?
|
| Mastitis | 1 | 2010 | 1 | 0.100 |
Why?
|
| Lupus Erythematosus, Discoid | 1 | 2010 | 10 | 0.090 |
Why?
|
| Lymphoma, Non-Hodgkin | 3 | 2000 | 42 | 0.090 |
Why?
|
| Carcinoma, Small Cell | 2 | 1996 | 71 | 0.090 |
Why?
|
| Liver Cirrhosis | 1 | 2010 | 60 | 0.090 |
Why?
|
| Pneumonia | 1 | 1991 | 67 | 0.090 |
Why?
|
| Hashimoto Disease | 1 | 2009 | 2 | 0.090 |
Why?
|
| Graves Disease | 1 | 2009 | 3 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 3 | 2006 | 260 | 0.090 |
Why?
|
| Aspergillus flavus | 1 | 2009 | 3 | 0.090 |
Why?
|
| Mediastinum | 1 | 2009 | 6 | 0.090 |
Why?
|
| Mediastinitis | 1 | 2009 | 6 | 0.090 |
Why?
|
| Aspergillosis | 1 | 2009 | 10 | 0.090 |
Why?
|
| BK Virus | 1 | 2009 | 10 | 0.090 |
Why?
|
| Histiocytoma, Benign Fibrous | 1 | 1989 | 6 | 0.090 |
Why?
|
| Leukocyte Count | 2 | 2019 | 92 | 0.090 |
Why?
|
| Enzyme Inhibitors | 2 | 2006 | 145 | 0.090 |
Why?
|
| Carcinoma, Bronchogenic | 1 | 1988 | 11 | 0.080 |
Why?
|
| Chondroblastoma | 1 | 2008 | 1 | 0.080 |
Why?
|
| Preoperative Period | 2 | 2019 | 65 | 0.080 |
Why?
|
| Genotype | 1 | 2009 | 405 | 0.080 |
Why?
|
| Granulosa Cells | 1 | 2008 | 4 | 0.080 |
Why?
|
| Cell Line, Tumor | 4 | 2012 | 265 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2014 | 162 | 0.080 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2020 | 170 | 0.080 |
Why?
|
| Microscopy, Electron | 4 | 1994 | 70 | 0.080 |
Why?
|
| Multivariate Analysis | 2 | 2014 | 324 | 0.080 |
Why?
|
| Metrorrhagia | 1 | 2007 | 1 | 0.080 |
Why?
|
| Chi-Square Distribution | 2 | 2012 | 145 | 0.080 |
Why?
|
| Transplantation, Homologous | 2 | 1999 | 277 | 0.080 |
Why?
|
| Streptococcal Infections | 1 | 2007 | 14 | 0.080 |
Why?
|
| Choristoma | 1 | 2007 | 8 | 0.080 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2006 | 22 | 0.070 |
Why?
|
| Adrenal Glands | 2 | 2018 | 8 | 0.070 |
Why?
|
| Chicago | 1 | 2009 | 865 | 0.070 |
Why?
|
| Metaplasia | 2 | 2018 | 11 | 0.070 |
Why?
|
| Cytogenetics | 1 | 2006 | 3 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2021 | 394 | 0.070 |
Why?
|
| ErbB Receptors | 1 | 2006 | 72 | 0.070 |
Why?
|
| ras Proteins | 1 | 2005 | 11 | 0.070 |
Why?
|
| Antibodies, Antinuclear | 1 | 2005 | 21 | 0.070 |
Why?
|
| Epstein-Barr Virus Nuclear Antigens | 1 | 2005 | 1 | 0.070 |
Why?
|
| Spleen | 2 | 2003 | 51 | 0.070 |
Why?
|
| Conjunctival Neoplasms | 1 | 2005 | 2 | 0.070 |
Why?
|
| Connexin 43 | 1 | 2005 | 8 | 0.070 |
Why?
|
| Heparin | 1 | 2005 | 26 | 0.070 |
Why?
|
| Pheochromocytoma | 2 | 1996 | 6 | 0.060 |
Why?
|
| Nuclear Envelope | 1 | 2004 | 6 | 0.060 |
Why?
|
| False Negative Reactions | 2 | 2002 | 13 | 0.060 |
Why?
|
| Proteinuria | 1 | 2005 | 81 | 0.060 |
Why?
|
| Splenic Diseases | 1 | 2003 | 3 | 0.060 |
Why?
|
| Analysis of Variance | 2 | 2014 | 321 | 0.060 |
Why?
|
| Neurilemmoma | 1 | 2004 | 13 | 0.060 |
Why?
|
| Kidney | 1 | 2005 | 173 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2021 | 1812 | 0.060 |
Why?
|
| Oncogene Proteins | 1 | 2003 | 7 | 0.060 |
Why?
|
| Immunoenzyme Techniques | 2 | 2003 | 40 | 0.060 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2023 | 6 | 0.060 |
Why?
|
| Proportional Hazards Models | 2 | 2014 | 340 | 0.060 |
Why?
|
| Ear, Middle | 1 | 2023 | 8 | 0.060 |
Why?
|
| Combined Modality Therapy | 1 | 2004 | 364 | 0.060 |
Why?
|
| Carboxypeptidases | 1 | 2022 | 6 | 0.060 |
Why?
|
| Estrogen Receptor alpha | 1 | 2022 | 15 | 0.060 |
Why?
|
| Tamoxifen | 1 | 2022 | 30 | 0.060 |
Why?
|
| Eyelid Neoplasms | 2 | 1995 | 3 | 0.060 |
Why?
|
| Basement Membrane | 2 | 2017 | 12 | 0.060 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2002 | 9 | 0.050 |
Why?
|
| Nuclear Pore Complex Proteins | 1 | 2002 | 4 | 0.050 |
Why?
|
| Antigens, Nuclear | 1 | 2002 | 2 | 0.050 |
Why?
|
| Child, Preschool | 2 | 2002 | 641 | 0.050 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2022 | 75 | 0.050 |
Why?
|
| Cell Cycle | 1 | 2002 | 41 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2019 | 1939 | 0.050 |
Why?
|
| Curettage | 1 | 2021 | 5 | 0.050 |
Why?
|
| Cervix Uteri | 1 | 2021 | 38 | 0.050 |
Why?
|
| Gene Rearrangement | 2 | 2015 | 10 | 0.050 |
Why?
|
| Environmental Exposure | 1 | 2021 | 15 | 0.050 |
Why?
|
| Margins of Excision | 1 | 2021 | 17 | 0.050 |
Why?
|
| Hematopoiesis, Extramedullary | 1 | 2000 | 2 | 0.050 |
Why?
|
| Particulate Matter | 1 | 2021 | 22 | 0.050 |
Why?
|
| Carcinosarcoma | 1 | 2000 | 4 | 0.050 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2000 | 12 | 0.050 |
Why?
|
| Salvage Therapy | 1 | 2021 | 36 | 0.050 |
Why?
|
| Cholangiocarcinoma | 1 | 2000 | 12 | 0.050 |
Why?
|
| Observer Variation | 1 | 2021 | 118 | 0.050 |
Why?
|
| Adrenal Cortex | 1 | 2020 | 1 | 0.050 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 2 | 0.050 |
Why?
|
| Kidney Pelvis | 1 | 2000 | 9 | 0.050 |
Why?
|
| Disease Progression | 2 | 2018 | 788 | 0.050 |
Why?
|
| Eye Neoplasms | 1 | 2000 | 5 | 0.050 |
Why?
|
| Mycobacterium xenopi | 1 | 2019 | 1 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2000 | 108 | 0.040 |
Why?
|
| Pancreatitis, Acute Necrotizing | 1 | 1999 | 2 | 0.040 |
Why?
|
| Platelet Activating Factor | 1 | 1999 | 8 | 0.040 |
Why?
|
| Leucine | 1 | 1999 | 15 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 1 | 1999 | 56 | 0.040 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2011 | 29 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2012 | 145 | 0.040 |
Why?
|
| Cecum | 2 | 2000 | 7 | 0.040 |
Why?
|
| RNA, Neoplasm | 2 | 2012 | 17 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2000 | 226 | 0.040 |
Why?
|
| Imidazoles | 1 | 1999 | 72 | 0.040 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2018 | 57 | 0.040 |
Why?
|
| Killer Cells, Natural | 2 | 2011 | 91 | 0.040 |
Why?
|
| Biodiversity | 1 | 2018 | 37 | 0.040 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 1997 | 2 | 0.040 |
Why?
|
| Cholestasis | 1 | 1997 | 8 | 0.040 |
Why?
|
| Mice | 1 | 2022 | 1620 | 0.040 |
Why?
|
| Recurrence | 1 | 2018 | 350 | 0.040 |
Why?
|
| Facial Pain | 1 | 2017 | 5 | 0.040 |
Why?
|
| Growth Hormone-Secreting Pituitary Adenoma | 1 | 2017 | 3 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2018 | 66 | 0.040 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 1 | 2017 | 5 | 0.040 |
Why?
|
| Vision Disorders | 1 | 2017 | 23 | 0.040 |
Why?
|
| Staphylococcus aureus | 1 | 2018 | 85 | 0.040 |
Why?
|
| Cadherins | 1 | 2017 | 31 | 0.040 |
Why?
|
| Pedigree | 1 | 2017 | 77 | 0.040 |
Why?
|
| Soft Tissue Infections | 1 | 1997 | 28 | 0.040 |
Why?
|
| Plasma Cells | 1 | 1997 | 8 | 0.040 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2018 | 79 | 0.040 |
Why?
|
| Headache | 1 | 2017 | 43 | 0.040 |
Why?
|
| Parathyroidectomy | 1 | 1997 | 9 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2018 | 86 | 0.040 |
Why?
|
| Epidermal Growth Factor | 1 | 1997 | 29 | 0.040 |
Why?
|
| Edema | 1 | 2017 | 38 | 0.040 |
Why?
|
| Paraganglioma, Extra-Adrenal | 1 | 1996 | 2 | 0.040 |
Why?
|
| Medical History Taking | 1 | 1997 | 24 | 0.040 |
Why?
|
| Pulmonary Embolism | 1 | 1997 | 59 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2012 | 483 | 0.040 |
Why?
|
| Pulmonary Alveolar Proteinosis | 1 | 1996 | 1 | 0.040 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 1 | 1996 | 4 | 0.040 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 1996 | 12 | 0.040 |
Why?
|
| Synovial Membrane | 1 | 1996 | 81 | 0.040 |
Why?
|
| Lung Diseases, Interstitial | 1 | 1996 | 12 | 0.040 |
Why?
|
| Transfection | 2 | 2006 | 125 | 0.040 |
Why?
|
| Lung | 1 | 1997 | 154 | 0.040 |
Why?
|
| Ifosfamide | 1 | 2015 | 8 | 0.030 |
Why?
|
| Synovial Fluid | 1 | 1996 | 123 | 0.030 |
Why?
|
| Etoposide | 1 | 2015 | 48 | 0.030 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 1995 | 4 | 0.030 |
Why?
|
| Apolipoproteins | 1 | 1995 | 9 | 0.030 |
Why?
|
| RNA-Binding Protein EWS | 1 | 2015 | 1 | 0.030 |
Why?
|
| Scalp Dermatoses | 1 | 1995 | 2 | 0.030 |
Why?
|
| Mandible | 1 | 2015 | 15 | 0.030 |
Why?
|
| Cisplatin | 1 | 2015 | 91 | 0.030 |
Why?
|
| Membrane Transport Proteins | 1 | 1995 | 50 | 0.030 |
Why?
|
| United States | 2 | 2019 | 2332 | 0.030 |
Why?
|
| North America | 1 | 2015 | 38 | 0.030 |
Why?
|
| Keratin-19 | 1 | 2014 | 1 | 0.030 |
Why?
|
| Europe | 1 | 2015 | 81 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2014 | 6 | 0.030 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2014 | 4 | 0.030 |
Why?
|
| Histocytochemistry | 1 | 1994 | 26 | 0.030 |
Why?
|
| Prostate | 1 | 1995 | 33 | 0.030 |
Why?
|
| Neoplasms, Post-Traumatic | 1 | 1994 | 1 | 0.030 |
Why?
|
| Up-Regulation | 2 | 2006 | 174 | 0.030 |
Why?
|
| Exons | 2 | 2005 | 34 | 0.030 |
Why?
|
| Spinal Neoplasms | 1 | 1994 | 36 | 0.030 |
Why?
|
| ROC Curve | 1 | 2014 | 138 | 0.030 |
Why?
|
| R Factors | 1 | 1994 | 2 | 0.030 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 1994 | 7 | 0.030 |
Why?
|
| Adrenal Gland Diseases | 1 | 1993 | 3 | 0.030 |
Why?
|
| Nevus, Pigmented | 1 | 1993 | 2 | 0.030 |
Why?
|
| Immunoblotting | 2 | 2005 | 55 | 0.030 |
Why?
|
| Escherichia coli | 1 | 1994 | 59 | 0.030 |
Why?
|
| Biomarkers | 1 | 2017 | 692 | 0.030 |
Why?
|
| Pharyngeal Neoplasms | 1 | 1993 | 4 | 0.030 |
Why?
|
| Mouth Neoplasms | 1 | 1993 | 17 | 0.030 |
Why?
|
| Coloring Agents | 1 | 2013 | 13 | 0.030 |
Why?
|
| In Situ Hybridization | 2 | 2003 | 46 | 0.030 |
Why?
|
| Radiography, Thoracic | 1 | 2012 | 28 | 0.030 |
Why?
|
| Aneuploidy | 1 | 1992 | 3 | 0.030 |
Why?
|
| Diploidy | 1 | 1992 | 4 | 0.030 |
Why?
|
| Dogs | 3 | 2000 | 253 | 0.030 |
Why?
|
| Zinc Finger Protein GLI1 | 1 | 2012 | 1 | 0.030 |
Why?
|
| Patched Receptors | 1 | 2012 | 1 | 0.030 |
Why?
|
| Patched-1 Receptor | 1 | 2012 | 1 | 0.030 |
Why?
|
| Smoothened Receptor | 1 | 2012 | 1 | 0.030 |
Why?
|
| Veratrum Alkaloids | 1 | 2012 | 1 | 0.030 |
Why?
|
| Cell Growth Processes | 1 | 2012 | 6 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2012 | 74 | 0.030 |
Why?
|
| Scleredema Adultorum | 1 | 1992 | 1 | 0.030 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2012 | 26 | 0.030 |
Why?
|
| Receptors, Cell Surface | 1 | 2012 | 50 | 0.030 |
Why?
|
| Phenotype | 1 | 2013 | 357 | 0.030 |
Why?
|
| Fever | 1 | 1992 | 40 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2012 | 170 | 0.030 |
Why?
|
| MicroRNAs | 1 | 2012 | 42 | 0.030 |
Why?
|
| Histoplasma | 1 | 1991 | 3 | 0.030 |
Why?
|
| Diagnostic Imaging | 1 | 2012 | 90 | 0.030 |
Why?
|
| Gallbladder Neoplasms | 1 | 2011 | 6 | 0.030 |
Why?
|
| Histoplasmosis | 1 | 1991 | 8 | 0.030 |
Why?
|
| Allopurinol | 1 | 2011 | 4 | 0.030 |
Why?
|
| DNA Damage | 1 | 2011 | 30 | 0.030 |
Why?
|
| Skin Diseases, Infectious | 1 | 1991 | 9 | 0.030 |
Why?
|
| Cell Death | 1 | 2011 | 61 | 0.020 |
Why?
|
| Neurosurgical Procedures | 1 | 2013 | 150 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2012 | 157 | 0.020 |
Why?
|
| Administration, Inhalation | 1 | 1991 | 25 | 0.020 |
Why?
|
| Drug Combinations | 1 | 1991 | 83 | 0.020 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1991 | 90 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2013 | 441 | 0.020 |
Why?
|
| Lymph Node Excision | 1 | 2010 | 26 | 0.020 |
Why?
|
| Trisomy | 1 | 2010 | 2 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2010 | 9 | 0.020 |
Why?
|
| Nephrectomy | 1 | 2010 | 29 | 0.020 |
Why?
|
| Knee Joint | 1 | 1996 | 797 | 0.020 |
Why?
|
| Microbiological Techniques | 1 | 2010 | 9 | 0.020 |
Why?
|
| Cecal Neoplasms | 1 | 1990 | 1 | 0.020 |
Why?
|
| Jejunal Neoplasms | 1 | 1990 | 2 | 0.020 |
Why?
|
| Pericardium | 1 | 1990 | 20 | 0.020 |
Why?
|
| Hepatitis C | 1 | 2010 | 65 | 0.020 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2009 | 17 | 0.020 |
Why?
|
| Antifungal Agents | 1 | 2009 | 36 | 0.020 |
Why?
|
| Radius | 1 | 1989 | 32 | 0.020 |
Why?
|
| Myocardium | 1 | 1990 | 140 | 0.020 |
Why?
|
| Bronchoscopy | 1 | 2008 | 25 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 1990 | 219 | 0.020 |
Why?
|
| Menstrual Cycle | 1 | 2007 | 27 | 0.020 |
Why?
|
| DNA, Antisense | 1 | 2006 | 1 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 2 | 1999 | 453 | 0.020 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily C | 1 | 2006 | 1 | 0.020 |
Why?
|
| Receptors, Natural Killer Cell | 1 | 2006 | 5 | 0.020 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2006 | 8 | 0.020 |
Why?
|
| Genes, ras | 1 | 2006 | 13 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2006 | 26 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2006 | 105 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2006 | 50 | 0.020 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2006 | 35 | 0.020 |
Why?
|
| Receptors, Immunologic | 1 | 2006 | 34 | 0.020 |
Why?
|
| Parasitic Diseases | 1 | 2005 | 4 | 0.020 |
Why?
|
| Rats | 2 | 1999 | 858 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2006 | 130 | 0.020 |
Why?
|
| Heparitin Sulfate | 1 | 2005 | 5 | 0.020 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2005 | 7 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2005 | 9 | 0.020 |
Why?
|
| Capillaries | 1 | 2005 | 11 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2005 | 17 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2005 | 22 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2005 | 31 | 0.020 |
Why?
|
| Antibodies, Neoplasm | 1 | 2005 | 10 | 0.020 |
Why?
|
| Glucose | 1 | 2005 | 59 | 0.020 |
Why?
|
| Cell Membrane Permeability | 1 | 2005 | 56 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2006 | 153 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2005 | 78 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2005 | 61 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2005 | 159 | 0.020 |
Why?
|
| Extracellular Matrix | 1 | 2005 | 74 | 0.020 |
Why?
|
| Autopsy | 1 | 2005 | 335 | 0.020 |
Why?
|
| DNA Probes | 1 | 2003 | 7 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2006 | 638 | 0.020 |
Why?
|
| Splenomegaly | 1 | 2003 | 3 | 0.020 |
Why?
|
| Splenic Neoplasms | 1 | 2003 | 2 | 0.020 |
Why?
|
| Gene Order | 1 | 2003 | 2 | 0.010 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2003 | 3 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2003 | 21 | 0.010 |
Why?
|
| Proteoglycans | 1 | 2005 | 337 | 0.010 |
Why?
|
| Postoperative Hemorrhage | 1 | 2003 | 24 | 0.010 |
Why?
|
| Intestinal Mucosa | 2 | 1997 | 220 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2003 | 323 | 0.010 |
Why?
|
| Culture Techniques | 1 | 2002 | 26 | 0.010 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2002 | 4 | 0.010 |
Why?
|
| Genetic Markers | 1 | 2002 | 58 | 0.010 |
Why?
|
| Probability | 1 | 2002 | 94 | 0.010 |
Why?
|
| Blood Cell Count | 1 | 2000 | 15 | 0.010 |
Why?
|
| Colony Count, Microbial | 1 | 2000 | 23 | 0.010 |
Why?
|
| Gram-Positive Bacteria | 1 | 2000 | 16 | 0.010 |
Why?
|
| Gram-Negative Bacteria | 1 | 2000 | 37 | 0.010 |
Why?
|
| Amylases | 1 | 1999 | 4 | 0.010 |
Why?
|
| C-Reactive Protein | 1 | 2000 | 125 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1999 | 215 | 0.010 |
Why?
|
| Medical Records Systems, Computerized | 1 | 1997 | 12 | 0.010 |
Why?
|
| Databases as Topic | 1 | 1997 | 19 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 1997 | 33 | 0.010 |
Why?
|
| Mastectomy | 1 | 1997 | 17 | 0.010 |
Why?
|
| Mesentery | 1 | 1997 | 4 | 0.010 |
Why?
|
| Serum Albumin, Bovine | 1 | 1997 | 8 | 0.010 |
Why?
|
| Ileum | 1 | 1997 | 22 | 0.010 |
Why?
|
| Laparotomy | 1 | 1997 | 21 | 0.010 |
Why?
|
| Blood Vessels | 1 | 1996 | 15 | 0.010 |
Why?
|
| Microcirculation | 1 | 1996 | 36 | 0.010 |
Why?
|
| Proteins | 1 | 1997 | 73 | 0.010 |
Why?
|
| Heart-Lung Transplantation | 1 | 1996 | 1 | 0.010 |
Why?
|
| Muromonab-CD3 | 1 | 1996 | 1 | 0.010 |
Why?
|
| Lip Neoplasms | 1 | 1996 | 2 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1997 | 251 | 0.010 |
Why?
|
| Clavicle | 1 | 1996 | 15 | 0.010 |
Why?
|
| Heart Transplantation | 1 | 1996 | 38 | 0.010 |
Why?
|
| Keratins | 1 | 1995 | 1 | 0.010 |
Why?
|
| Lactalbumin | 1 | 1995 | 1 | 0.010 |
Why?
|
| Apolipoproteins D | 1 | 1995 | 1 | 0.010 |
Why?
|
| Bacteria | 1 | 1996 | 77 | 0.010 |
Why?
|
| Carcinoembryonic Antigen | 1 | 1995 | 6 | 0.010 |
Why?
|
| Bacterial Infections | 1 | 1996 | 69 | 0.010 |
Why?
|
| Thyroiditis | 1 | 1995 | 1 | 0.010 |
Why?
|
| Dermatology | 1 | 1995 | 6 | 0.010 |
Why?
|
| Glycoproteins | 1 | 1995 | 58 | 0.010 |
Why?
|
| Multiple Sclerosis | 1 | 1996 | 87 | 0.010 |
Why?
|
| Cell Division | 1 | 1995 | 114 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 1995 | 97 | 0.010 |
Why?
|
| Medical Oncology | 1 | 1995 | 32 | 0.010 |
Why?
|
| Hemorrhage | 1 | 1995 | 75 | 0.010 |
Why?
|
| Kanamycin Resistance | 1 | 1994 | 1 | 0.010 |
Why?
|
| Necrosis | 1 | 1992 | 26 | 0.010 |
Why?
|
| Hypergammaglobulinemia | 1 | 1992 | 3 | 0.010 |
Why?
|
| Immunoglobulin Light Chains | 1 | 1992 | 9 | 0.010 |
Why?
|
| Cytoplasmic Granules | 1 | 1990 | 9 | 0.010 |
Why?
|
| Mucins | 1 | 1990 | 6 | 0.010 |
Why?
|
| Length of Stay | 1 | 1992 | 317 | 0.010 |
Why?
|